Business Context and Reporting Period
Pacific Biosciences of California, Inc. filed this Form 8-K on October 23, 2014, to report financial results for the quarter ended September 30, 2014. The company operates in the genomics sector, delivering PacBio RS II sequencing systems and recognizing revenue from contractual agreements, including a milestone payment from Roche.
Key Financial Metrics
- Revenue: $20.6 million for Q3 2014, driven by six instrument deliveries and a $10.0 million Roche milestone.
- Gross Profit: $13.2 million, representing a gross margin of 63.8%.
- Operating Expenses: $21.6 million, including $2.2 million in non-cash stock-based compensation.
- Net Loss: $9.2 million for the quarter.
- Liquidity: Cash and investments totaled $99.3 million as of September 30, 2014.
- Backlog: 20 instruments as of September 30, 2014.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased from $7.4 million in Q3 2013 to $20.6 million in Q3 2014, primarily due to the $10.0 million Roche milestone.
- Margin Expansion: Gross margin improved significantly from 16.7% in Q3 2013 to 63.8% in Q3 2014 due to the mix of contractual revenue.
- Loss Reduction: Net loss narrowed from $20.5 million in Q3 2013 to $9.2 million in Q3 2014.
- Cash Position: Cash and investments decreased from $112.5 million at year-end 2013 to $99.3 million at September 30, 2014, excluding proceeds from an "at-the-market" offering.
Guidance, Outlook, and Risks
- Revenue Guidance: The company expects total 2014 revenue to be at least $58 million.
- Margin Outlook: Gross margin is expected to decrease in the short term due to a higher mix of instrument revenue and the non-recurring nature of the Q3 milestone.
- Expense Outlook: Quarterly operating expenses are anticipated to remain near current levels for the remainder of 2014.
- Risks: The filing contains forward-looking statements subject to risks and uncertainties; actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the sustainability of gross margins given the non-recurring $10.0 million Roche milestone.
- Confirm the status of the 20-instrument backlog and expected delivery timelines.
- Review the cash burn rate, noting the $36.1 million used in operating activities over the nine-month period.
- Assess the impact of the "at-the-market" offering program on future dilution and liquidity.